[{"data":1,"prerenderedAt":211},["ShallowReactive",2],{"drug-fenofibrate":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":20,"formulations":24,"regimens":47,"contraindications":106,"warnings":116,"renal":117,"monitoring":118,"interactions":119,"review":120,"examples":123,"atc":134,"iran":136,"links":156,"populations":173,"usApproval":206},"fenofibrate",1,{"fa":7,"en":8},"فنوفیبرات","Fenofibrate","cardiovascular",{"fa":11,"en":12},"فیبرات","Fibrate",[14,17],{"name":15,"market":16},"Tricor","US",{"name":18,"market":19},"Lipanthyl","GB",[21,22,23,7],"tricor","lipanthyl","لیپانتیل",[25,39],{"id":26,"form":27,"route":28,"label":29,"concentration":30,"markets":34,"refs":35},"tab-54","tablet","oral","54 mg tablet",{"amount":31,"unit":32,"perUnit":27,"scored":33},54,"mg",false,[16],[36],{"source":37,"section":38},"fda-fenofibrate","3",{"id":40,"form":27,"route":28,"label":41,"concentration":42,"markets":44,"refs":45},"tab-160","160 mg tablet",{"amount":43,"unit":32,"perUnit":27,"scored":33},160,[16],[46],{"source":37,"section":38},[48,67,91],{"id":49,"disease":50,"label":51,"population":54,"type":58,"unit":32,"dose":59,"refs":60,"limits":63},"lipid","hyperlipidemia",{"fa":52,"en":53},"هیپرکلسترولمی یا دیس‌لیپیدمی مختلط — ۱۶۰ mg یک بار","Primary hypercholesterolaemia or mixed dyslipidaemia — 160 mg once daily",{"minAge":55},{"value":56,"unit":57},18,"year","fixed",{"perDose":43,"dosesPerDay":5},[61],{"source":37,"section":62},"2.2",{"maxPerDay":43,"refs":64},[65],{"source":37,"section":66},"2.3",{"id":68,"disease":69,"label":70,"population":73,"type":58,"unit":32,"dose":75,"refs":76,"limits":78,"notes":81},"tg","hypertriglyceridemia",{"fa":71,"en":72},"تری‌گلیسرید شدید — ۵۴ تا ۱۶۰ mg یک بار","Severe hypertriglyceridaemia — 54–160 mg once daily",{"minAge":74},{"value":56,"unit":57},{"perDose":31,"perDoseMax":43,"dosesPerDay":5},[77],{"source":37,"section":66},{"maxPerDay":43,"refs":79},[80],{"source":37,"section":66},[82],{"text":83,"refs":86},{"fa":84,"en":85},"نارسایی خفیف تا متوسط کلیه: شروع ۵۴ mg. اگر پس از ۲ ماه با ۱۶۰ mg پاسخ نبود، قطع شود.","Mild–moderate renal impairment: start 54 mg. Stop if no response after 2 months on 160 mg.",[87,89],{"source":37,"section":88},"2.4",{"source":37,"section":90},"2.1",{"id":92,"disease":50,"label":93,"population":96,"type":98,"unit":32,"dose":99,"refs":103},"peds",{"fa":94,"en":95},"زیر ۱۸ سال","Under 18 years",{"maxAge":97},{"value":56,"unit":57},"notCalculated",{"reason":100},{"fa":101,"en":102},"بی‌خطری و اثربخشی در کودکان ثابت نشده است.","Safety and effectiveness in children not established.",[104],{"source":37,"section":105},"8.4",[107],{"id":108,"severity":109,"text":110,"refs":113},"ci","block",{"fa":111,"en":112},"نارسایی شدید کلیه یا دیالیز؛ بیماری فعال کبد؛ بیماری کیسه صفرا؛ شیردهی؛ حساسیت.","Severe renal impairment or dialysis; active liver disease; gallbladder disease; breastfeeding; hypersensitivity.",[114],{"source":37,"section":115},"4",[],[],[],[],{"status":121,"reviewer":122,"date":122},"unverified",null,[124,129],{"regimen":49,"formulation":40,"input":125,"expect":128},{"ageYears":126,"weightKg":127},55,85,{"perDose":43},{"regimen":68,"formulation":26,"input":130,"expect":133},{"ageYears":131,"weightKg":132},50,90,{"perDose":31},[135],"C10AB05",{"status":137,"forms":138,"refs":151},"registered",[139,143,147],{"code":140,"en":141,"fa":142},"10932","FENOFIBRATE 100MG CAP","کپسول فنوفیبرات ۱۰۰ میلی‌گرم",{"code":144,"en":145,"fa":146},"05992","FENOFIBRATE 200MG CAP","کپسول فنوفیبرات ۲۰۰ میلی‌گرم",{"code":148,"en":149,"fa":150},"08012","FENOFIBRATE 67MG CAP","کپسول فنوفیبرات ۶۷ میلی‌گرم",[152],{"source":153,"section":154,"url":155},"darooyab-generic","G-1680\u002FFenofibrate","https:\u002F\u002Fwww.darooyab.ir\u002FG-1680\u002FFenofibrate",[157,161,165,168,171],{"kind":158,"url":159,"label":160},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=207803","ANDA207803",{"kind":162,"url":163,"label":164},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=a97ebf51-4f68-4426-9958-5c59f91b1d47","FDA Fenofibrate",{"kind":166,"url":167,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa601052.html",{"kind":169,"url":170,"label":135},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C10AB05",{"kind":172,"url":155,"label":8},"darooyab",{"pregnancy":174,"lactation":183,"pediatric":191,"geriatric":198},{"level":175,"text":176,"quote":179,"refs":180},"caution",{"fa":177,"en":178},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited available data with fenofibrate use in pregnant women are insufficient to determine a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.",[181],{"source":37,"section":182},"8.1",{"level":184,"text":185,"quote":188,"refs":189},"contraindicated",{"fa":186,"en":187},"برچسب: در شیردهی منع مصرف دارد.","Label: contraindicated while breastfeeding.","… arnings and Precautions (5.2) ] . patients with preexisting gallbladder disease [see Warnings and Precautions (5.5) ] . nursing mothers [see Use in Specific Populations (8.2) ] . patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions (5.9) ] .",[190],{"source":37,"section":115},{"level":175,"text":192,"quote":195,"refs":196},{"fa":193,"en":194},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness have not been established in pediatric patients.",[197],{"source":37,"section":105},{"level":175,"text":199,"quote":202,"refs":203},{"fa":200,"en":201},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Since elderly patients have a higher incidence of renal impairment, dose selection for the elderly should be made on the basis of renal function [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3) ] .",[204],{"source":37,"section":205},"8.5",{"kind":207,"refs":208,"id":160},"ANDA",[209],{"source":37,"section":210},"SPL approval \u002F marketing category",1792440728340]